Skip to Main Content

DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

About this study

This study will enroll participants with rhabdomyosarcoma (RMS), non-RMS soft-tissue sarcoma, osteosarcoma and Ewing sarcoma. The doctors in this study would like to see if they can reduce the patient’s exposure to the harmful effects of ionizing radiation by replacing imaging studies that use radiation with whole body diffusion weighted magnetic resonance imaging (DW-MRI), which does not use any radiation.

They will also see if DWI MRI can tell how well pediatric sarcomas are responding to treatment. There have been some studies in adults with cancer that have shown that DWI-MRI provides useful information about tumors responding to therapy. However there have only been very small studies of DWI-MRI in children with tumors in the body. Therefore, the role of DW-MRI in pediatric sarcoma patients is not yet known and is still experimental.

Eligibility overview

  • This is a non-therapeutic clinical trial that is only open to St. Jude patients.
  • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment.
  • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
  • Participant meets institutional MRI safety screening requirements. 
  • Participant has not undergone primary tumor resection prior to arrival to St. Jude. 

Note: If participant requires sedation, he/she must not have an acute cardiopulmonary process including, but not limited to croup, reactive airways disease, pneumonia, clinical or radiological evidence or pericardial effusion or other cardiopulmonary disease.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

Study goal:

To estimate the ability of the whole body diffusion weighted MRI (WB DWI) to correctly identify pediatric sarcoma patients with and without bone/bone marrow and soft-tissue metastases at the time of diagnosis. 

To determine the correlation between changes in primary pediatric sarcoma 18-F fluorodeoxyglucose positron emission tomography (FDG PET) maximum standardized uptake values (SUVmax) and average DWI apparent diffusion coefficient (ADC) values from baseline (pre-treatment) to just prior to local control. 


Solid tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more